4D Molecular Therapeutics (FDMT) Net Cash Flow (QoQ) (2020 - 2026)
Powered by 
Analysis
4D Molecular Therapeutics (FDMT) Net Cash Flow (QoQ) (2020 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 1.05 Bn | 692.04 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -117.28% |
| Mar 31, 2026 | 4.80% |
| Dec 31, 2025 | 140.85% |
| Sep 30, 2025 | 49.25% |
| Jun 30, 2025 | -256.53% |
| Mar 31, 2025 | 58.62% |
| Dec 31, 2024 | -2,410.05% |
| Sep 30, 2024 | 98.24% |
| Jun 30, 2024 | -426.71% |
| Mar 31, 2024 | 199.68% |
| Dec 31, 2023 | -167.49% |
| Sep 30, 2023 | -75.04% |
| Jun 30, 2023 | 501.66% |
| Mar 31, 2023 | 146.86% |
| Dec 31, 2022 | -978.81% |
| Sep 30, 2022 | -113.82% |
| Jun 30, 2022 | 148.70% |
| Mar 31, 2022 | -224.22% |
| Dec 31, 2021 | 140.60% |
| Sep 30, 2021 | -847.49% |